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Abstract: Microbial infections are still among the major public health concerns since several yeasts
and fungi, and other pathogenic microorganisms, are responsible for continuous growth of infections
and drug resistance against bacteria. Antimicrobial resistance rate is fostering the need to develop new
strategies against drug-resistant superbugs. Antimicrobial peptides (AMPs) are small peptide-based
molecules of 5–100 amino acids in length, with potent and broad-spectrum antimicrobial properties.
They are part of the innate immune system, which can represent a minimal risk of resistance
development. These characteristics contribute to the description of these molecules as promising
new molecules in the development of new antimicrobial drugs. However, efforts in developing new
medicines have not resulted in any decrease of drug resistance yet. Thus, a technological approach
on improving existing drugs is gaining special interest. Nanomedicine provides easy access to
innovative carriers, which ultimately enable the design and development of targeted delivery systems
of the most efficient drugs with increased efficacy and reduced toxicity. Based on performance,
successful experiments, and considerable market prospects, nanotechnology will undoubtedly lead a
breakthrough in biomedical field also for infectious diseases, as there are several nanotechnological
approaches that exhibit important roles in restoring antibiotic activity against resistant bacteria.
Keywords: antimicrobial peptides; bacterial and virus infections; coronavirus; antimicrobial
resistance; nanomaterials; nanomedicine
1. Introduction
The discovery of new antimicrobial molecules in the early 1920s was a landmark in the field of
pharmacology allowing the reduction of morbidity and mortality from infectious diseases, which were
among the main causes of death worldwide [1]. However, the widespread and indiscriminate use of
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powerful antibiotics in recent decades has led to a dramatic increase in microbial resistance, being
nowadays a major threat to global public health [2]. There is a long list of identified drug-resistant
bacteria, including sulfonamide-resistant, penicillin-resistant, methicillin-resistant, macrolide-resistant
and vancomycin-resistant, or even multidrug-resistant. As a result, drug-resistant bacterial infections
can result in the need to use a higher drug dosage, higher toxicity treatments and longer hospitalization
periods, ultimately translated in increased mortality, thus negatively affecting both medicine and
society [3]. Antimicrobial resistance is, nowadays, one of the major global economic and healthcare
burdens and, despite the efforts in research and development of new molecular entities, the pipeline
for new drugs tends to grow on empty [1].
Bacteriocins are peptides produced mainly by Gram-positive bacteria with the main purpose of
self-preservation, while a large portion of Gram-negative bacteriocins resemble eukaryotic antimicrobial
peptides such as defensins [4]. These antimicrobial peptides depict amphiphilic helices, differing
among them in mode of action, biochemical properties and thus spectrum of activity. They are classified
according to the host producer, intrinsic function, molecular weight, physicochemical properties and
amino acid sequence. Meade et al. published a comprehensive analysis of their classification and
use against multi-drug-resistant species [4]. Antimicrobial peptides (AMPs) are small peptide-based
molecules, 5–100 amino acids in length, with potent and broad-spectrum antimicrobial properties.
AMPs are considered among the most promising drug candidates to be used against infections with
the aim to overcome microbial drug resistance. However, they also display some limitations regarding
bioavailability and safety, and may possess additional biological activities and functions. AMPs can
indeed be used as signaling molecules, in tissue regeneration, as biomarkers and even as tumoricidal
agents. AMPs are produced by nearly all living organisms and they act by binding to genetic material,
by interacting with the cell wall, cell membrane and/or with intracellular organelles. They act by
protecting plants against fungal and bacterial invasions, while in invertebrates and vertebrates they
also have activity against parasite and viral invasions which may induce toxic events in the host
eukaryotic cells. Table 1 summarizes their main mechanistic pathways. While the mechanisms of action
of AMPs have not yet been fully described [5], it is known that AMPs can have receptor-mediated
or non-receptor-mediated interactions with the cell membrane [6]. Most of the AMPs produced by
bacteria undergo receptor-mediated interactions and are active in vitro at very low concentrations.
However, in most vertebrates and invertebrates, AMPs target the membrane without specifically
interacting with receptors and are active at concentrations in the micromolar range. They interact
with components of the membrane, i.e., with the negative charge of lipids (e.g., lipopolysaccharides,
cardiolipin) which attract the positively charged AMPs. Other AMPs may target the bacterial cell wall,
inhibit cell wall synthesis or have intracellular targets. While most of the conventional antibiotics
compromise the synthesis of cell wall components by binding to specific proteins involved in the
reaction, AMPs often interact with precursor molecules needed for the synthesis of the cell wall. As
AMPs are produced by several immune cells (e.g., macrophages, neutrophils), the peptides can also
activate immune cells which may result in increased microbial killing and/or control of inflammation.
Table 1. Mechanisms of action of antimicrobial peptides.
AMPs Action Effects
Membrane-targeting
(direct cell killing)
Cell membrane disruption
Specific binding to membrane receptors
Nonmembrane-targeting
(immune modulation) Activation of immune cells
Controlled inflammation
Increased killing and clearance of
pathogenic microorganisms
AMPs can also act as delivery systems as an alternative over conventional antibiotics [7],
in particular, against nosocomial infections caused by multidrug resistant Gram-negative pathogens [4].
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Burrer et al. have used several strains of murine coronavirus in cell culture and in vivo in mouse models
for the assessment of the antiviral properties of peptide-conjugated antisense phosphorodiamidate
morpholino oligomers (P-PMOs) [8]. The authors have reported the targeting effect of P-PMOs against
various target sites in the viral genome in cell culture and protected mice against virus-induced tissue
damage. Ykeda et al. have used an antimicrobial peptide isolated from the skin of Xenopus tropicalis
(Pxt-5), and its modified peptide (Modify-Pxt-5) to produce self-assembled discoidal nanoparticles
composed of amphiphilic alpha-helical scaffold proteins or peptides organised in a lipid bilayer [9].
Both the peptides Pxt-5, having hydrophobic and hydrophilic faces, behaved like general surfactants
and can be used as carriers. Bacteriocins, while very active at low concentrations, usually have low
in vivo stability, being susceptible to degradation by proteolytic enzymes [4]. Another major limitation
on the use of these peptides is the difficulty encountered in their large-scale production, compromising
altogether their clinical application. An approach to overcome their limited stability in vivo is their
loading into nanoparticles.
Nanomedicine is currently a well-established approach intimately related to the design
and development of nanomaterials with unique therapeutic and diagnostic properties [10].
Nanotechnologies have also shown great potential in almost every aspect of the management of
microbial infection with more than ten nanoparticles (NPs)-based products marketed for bacterial
diagnosis, antibiotic delivery and medical devices in 2014. With unique physicochemical characteristics,
nanomaterials are sensitive and selective in the detection of bacterial signalling and may also exbibit
intrinsic antimicrobial properties. Furthermore, nanomaterials can be used for antimicrobial drug
delivery, and the incorporation of antimicrobial nanomaterials in medical devices and implants can
prevent microbial adhesion and infection [11,12]. All these facts are instrumental against antimicrobial
resistance by compromising bacterial mechanisms of resistance [13]. Focusing on nanomaterials-based
drug delivery systems, these offer an improved strategy to increase the therapeutic index, by decreasing
the dosage and frequency of administration. Besides, nanomaterials promote intracellular drug delivery,
mitigating the development of drug-resistant bacteria and also allowing targeted organ accumulation
by functionalized surface modifications, thus limiting systemic side effects and immunosuppression [2].
Despite these promising outcomes, the main challenge of establishing clinical use is related to the
evaluation of interactions of nano-antibiotics with cells, tissues and organs achieving information
about their possible toxic effects, together with the production on a large scale [1,14,15].
Several types of nanomaterials have shown potential in the pharmaceutical field. They have
also been studied as potential drug carriers with applications in the delivery of AMPs, promising
antimicrobial molecules which, due to their nature and physicochemical characteristics, have limited
bioavailability. The aim of this work is to revise the state-of-the-art on the approach that combines
the advantages of the design of new drug delivery systems for the improvement of antimicrobial
bioavailability, taking into account the recent developments in nanomaterials for antimicrobial
peptide delivery.
2. Antimicrobial Peptides (AMPs): New Additions to the Therapeutic Arsenal
AMPs are small natural oligopeptides that have recently showed a potential activity against
antibiotics resistance mechanisms, due to their ability in lysing bacterial membranes, thus providing
broad-spectrum effects, targeting microorganisms from viruses to parasites. The main interesting
property of AMPs is their ability to selectively disrupt bacterial membranes without affecting
mammalian cells, thus being safe. In addition, AMPs are referred to in the literature as host-defence
peptides with anti-inflammatory and anticancer activities, because they are synthesized molecules
that take action on the defence mechanisms against biological threats of the living organism of
origin [16]. The discovery of AMPs dates back to the first half of the 20th century when in 1939, Dubos
extracted an antimicrobial agent from a soil Bacillus strain, proven to be effective in mice pneumococci
infection. This extract was then fractioned allowing the identification of gramicidin. Despite some
systemic toxicity, gramicidin has shown to be effective in the topical treatment of wounds and ulcers.
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The first animal-originated AMP to be reported is defensin, isolated from rabbit leukocytes in 1956 [17].
Nowadays, more than 2000 AMPs have been described and current molecular developments can
be consulted in a series of databases available on the web (Table 2), including natural identified
molecules, as well as peptidomimetic molecules and analogues that are pharmacologically designed
thanks to the use of bioinformatics [18]. Current Food and Drug Administration (FDA)-approved
AMPs with well-established use include bacitracin, colistin and polymyxin B (although only for topical
administration) [2].
Table 2. Currently available AMPs databases.
Database Description
Collection of antimicrobial peptides (CAMP) Holds experimentally validated and predicted AMP sequences
AMPer Database and automated discovery tool forgene-coded AMPs
Antimicrobial Peptide Database (APD) Contains mostly AMPs from natural sources(~98% of the entries)
Yet Another Database of Antimicrobial
Peptides (YADAMP) Mostly focused on bacterial AMPs
BACTIBASE Data repository of bacteriocin AMPs
PhytAMP Database dedicated to antimicrobial plant peptides
RAPD Database containing recombinantly-produced AMPs
HIPdb Experimentally validated HIV inhibitory peptides
Bagel2 Bacteriocin mining tool
Peptaibol Database for peptaibols (unusual peptides)
PenBase Database devoted to penaeidins
Defensins Knowledge Base Information and database dedicated to defensins
CyBase Database specialized in cyclotides
Despite the lack of consensus on the influence of peptide sequence in biologic activity of AMPs,
some common characteristics seem to be important and fairly related to their antimicrobial property.
The main one is primarily charge, with 90% of AMPs being cationic, and secondly, hydrophobicity
or amphipathicity, influencing solubility profiles and consequently bioavailability [19]. Associated
with structural characteristics, these are also the main physicochemical properties that should also be
taken into account in the design of new synthetic AMPs [17]. Compared to conventional antibiotics,
AMPs demonstrate significant advantages such as potency and board spectrum of activity, as well
as an additional activity to modulate the immune system responses and low resistance rates. They
also show some limitations that impair their safe therapeutic use, such as sensitivity to proteolysis,
influencing stability and undefined toxicological data for systemic use [20]. In addition, their cationic
and amphiphilic nature lead to high binding to serum proteins after parenteral administration, with
consequent rapid elimination from bloodstream circulation and accumulation in the reticuloendothelial
system, thus resulting in toxic effects and reduced activity [21]. To overcome these limitations, some
strategies have been developed, maximizing the proven therapeutic potential of AMPs. There are
numerous methods for obtaining AMP delivery systems. AMPs could be immobilized onto a variety
of materials or onto a variety of surfaces and still retain their antibacterial activity. Also, AMPs can be
targeted through loading them in nanoparticulate systems with selective delivery capacities, including
polymers, liposomes, hydrogels, nanospheres, nano-capsules and carbon nanotubes [19]. As practical
examples on of these of strategies, the studies of Mishra et al. were focused on the development of an
AMP-coated surface, specifically immobilizing Lassioglossin-III onto silicone-based catheters and its
activity against urinary tract infections [22]. At the same time, Water et al. developed the possibility of
encapsulating plectasin, a cationic AMP, into polymeric NPs and evaluated their efficacy on S. aureus
strains [23].
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3. Nano-Antibiotics: Nanomaterials for Infection Control
Bacteria show resistance to antibiotics drugs through a variety of mechanisms. Moreover,
the development of even new mechanisms of resistance has resulted in the simultaneous development
of resistance to several antibiotic classes creating very dangerous multidrug-resistant (MDR) bacterial
strains [24,25]. However, when bacteria are drug-resistant it does not mean that they stop responding
to an antibiotic, but that occurs only at higher concentrations [26,27]. Of greater concern are cases
of acquired resistance, where initially susceptible populations of bacteria become resistant to an
antibacterial agent, in particular antibiotics, and proliferate and spread under the selective pressure of
use of that drug. One approach to address this challenge is to design analogues of drugs [28,29] that
are already in clinical use and that have activity against resistant organisms. However, bacteria are
constantly succeeding to develop a resistant mechanism to new antibiotic drugs as well as to their
analogues [30,31].
Nanotechnology offers opportunities to re-explore the biological properties of already known
antimicrobial compounds such as antibiotics by manipulating their size to modify their effect.
The combination of AMPs with nanomaterials is not new. Out of the available 71,102 papers
indexed in the Web of Science, a total of 70,948 combining AMPs with nanoparticles or nanomaterials
have been published over the last 20 years in a range of disciplines (Figure 1).
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Evidence collected in the revie work of Huh and Kwon [1], Pelgrift and Friedman [3], Brooks
and Brooks [2], Diab et al. [32] and Shimanovich and Gedanken [33] clarifies microbial drug resistance
mechanisms and how nanotechnology may be considered a tool against this issue. Development of drug
resistance occurs in (at least) three steps: (i) acquisition by microbes of resistance genes; (ii) expression
of those resistance genes; (iii) selection for microbes expressing those resistance genes. First, bacteria
acquire resistance to single and multiple drugs through horizontal gene transfer by transformation,
conjugation and transduction [34]. Bacteria can also acquire resistance genes by spontaneous mutation
of existing genes [35]. MDR is acquired when a bacterial cell already containing one type of drug
resistance gene acquires another type of drug resistance gene [34,36]. Second, in response to exposure to
an antimicrobial drug, microbes express the resistance gene [36]. Third, resistance becomes widespread
when there is selection for microbes that express resistance genes against the antimicrobial drug. This
selective pressure in favour of resistance occurs whenever microbes are exposed to the drug but not
eradicated (either by the microbicidal effects of the drug itself or by microbiostatic effects of the drug
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followed by killing by the host’s immune system) [34]. A schematic representation of some specific
mechanisms of antimicrobial drug resistance is shown in Figure 2.
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Nanomaterials (Figure 3), which either show antimicrobial activity by themselves or elevate the
effectiveness and safety of antibiotics administration [10,13], are called “nano-antibiotics” and their
capability of controlling infections in vitro and in vivo has been explored and demonstrated. Unlike
many antimicrobial agents currently being used in the clinic, antimicrobial NPs may not pose direct
and acute adverse effects, although potential toxicity upon long-term exposure is questionable. Most
importantly, antimicrobial NPs tackle multiple biological pathways found in broad species of microbes
and many concurrent mutations would have to occur to develop resistance against NPs’ antimicrobial
activities. Preparation of antimicrobial NPs could be cost-effective, compared to antibiotics synthesis,
furthermore they are stable enough for long-term storage with a prolonged shelf-life [37]. In addition,
some NPs can withstand harsh conditions, such as high-temperature sterilization, under which
conventional antibiotics are inactivated. Antibiotics delivery using nanomaterials offer multiple
advantages: (i) controllable and relatively uniform distribution in the target tissue; (ii) improved
solubility; (iii) sustained and controlled release; (iv) improved patient-compliance; (v) minimized side
effects; and (vi) enhanced cellular internalization [16,37].
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4. Advances in Nanomaterials for AMP Delivery
Current advances in the use of inorganic nanoparticles for AMP delivery involve essentially
the development of silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs), as well as
silicon derivates nano-systems [38]. The studies revised in this work are summarized in Table 3.
The development of polymeric nanoparticles for AMP delivery may offer an excellent technological
strategy to improve drug bioavailability and safety, avoiding drug chemical and enzymatic degradation,
preventing aggregation, enhancing controlled release. Chitosan (CS) NPs (CSNPs) are particularly
interesting as the broad spectrum of antibacterial activity of CS is well known and documented, offering
the possibility of synergistic effects with antimicrobial molecules. Moreover, due to its biocompatibility
properties, CS nanostructures have been extensively studied for drug delivery, and that is no different
for AMP delivery.
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Table 3. Recent studies on inorganic nanoparticles for AMP delivery.
System AMP Study Description Authors
Au nanoparticles
Photoluminescent gold
nanodots (AuNDs) Surfactin
AuNDs functionalized with hybridized ligands, an antimicrobial peptide
(surfactin; SFT), and 1-dodecanethiol (DT), on Au NPs, for application in wound
infection treatment.
Chen et al. [39]
AuNPs
Cecropin melittin
Magainin-1
Tet-20
Development of a one-step synthetic route form functionalization
of AuNPs with AMPs Rai et al. [40]
AuNPs Anti-apoptotic peptide Modulation of the anti-cancer effects of the selected peptides Akrami et al. [41]
Ag nanoparticles
AgNPs Ampicillin Polymersomes for the conjugation of AgNPs with ampicillin, to achievesynergistic effects Geilich et al. [42]
AgNPs nanofiber PAs Study of metallized organic nanofibers for application in wound infection treatment Pazos et al. [43]
AgNPs MBP-1 Study of the synergistic antibacterial effect of plant peptide MBP-1 and AgNPs oninfected wounds caused by S. aureus Salouti et al. [44]
Ag-coated nanotubes T 359 Study of additive antimicrobial effects between nanotubes and AMP T 359 Chaudhari et al. [45]
Si nanoparticles
Anionic mesoporous SiNPs LL-37 Study of membrane interaction with AMPs in different types of mesoporous particles. Braun et al. [46]
Nanospheres Trichogin GA IVAmpullosporin A
Study of AMPs properties adsorbed on silica-based surfaces for potential applications
in intracellular drug delivery Syryamina et al. [47]
Nano-clays NisinPediocin Study of nano-clays as nano-carriers for nisin and pediocin adsorption,for applications in food industry. Meira et al. [48]
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4.1. Inorganic or Metallic Nanostructures for AMP Delivery
In recent years, an increasing number of papers reporting on a new generation of antimicrobial
metallic NPs has been published [38]. Consequently, many of the information on the application
of nanotechnology in the infectious disease field regards the use of silver (Ag) and gold (Au)
NPs [11,12,49]. Recently, derivatives of other metals have been studied for antimicrobial applications,
and the antibacterial effects of zero-valent bismuth NPs and uncoated Au, nickel (Ni) and silicon (Si)
NPs were reported [50,51]. Despite the demonstrated intrinsic antimicrobial properties, dispersed
metallic NPs tend to aggregate and separate in solution, resulting in a decrease in their antimicrobial
efficiency. With the aim of improving antibacterial properties, functionalization of NPs has been
attempted with surfactants, polymers or antibiotics resulting in more stable, less aggregated NPs
suspension and innovative, synergistic antibacterial agents. For instance, silver NPs stabilized by
polymers(polyvinylpyrrolidone) and surfactants (SDS and Tween 80) exhibit enhanced antibacterial
activities [52]. NPs can also act as drug-carriers able to pass through cell membranes [53,54]. Widely
used antibiotics such as ciprofloxacin may benefit from the association with NPs, and conjugation
may result in an antibacterial effect also against micro-organisms resistant to the same molecule in the
naturally occurring form [55]. When the antimicrobial agents are covalently linked to or contained
within, NPs, a higher drug concentration is attained in the area of interest, resulting in better efficacy
at comparable doses and in slower release over time that may be exploited for preventing bacterial
colonization [56,57]. Moreover, specific biological sites can be attacked after modification of NPs with
target molecules [58,59]. As the NPs themselves may have antibacterial properties, the combination
of NPs and loaded drugs exert a synergistic action [60]. Current advances in the use of inorganic
nanostructures for AMP delivery involve essentially the development of Ag and AuNPs, as well as
silicon derivate nano-systems. The studies revised in this work are summarized in Table 3.
4.1.1. Gold Nanoparticles
Research on gold NPs is increasing thanks to their many advantages, such as their ease of
synthesis and conjugation to biomolecules, their capability to maintain their own structure when in
circulation and their improved effectiveness against bacteria, thus demonstrating their high potential
in the field of nanomedicine. Even if at the beginning, the research in this field was focused on the
possibility to exploit gold NPs in combination to laser radiation, thus significantly reducing bacteria
viability due to cell lysis and mechanical disruption [61]. Currently, two recent studies have been
reported exploring the use of Au nanostructures for AMP delivery. Photoluminescent Au nanodots
(AuNDs) were prepared by Chen et al. [39]. These AuNDs were functionalized with hybridized
ligands, an antimicrobial peptide (surfactin; SFT), and 1-dodecanethiol (DT), on AuNPs. Ultrasmall
SFT/DT–Au NDs (size ≈ 2.5 nm) were achieved and exhibited highly efficient antimicrobial activity.
The photoluminescence properties and stability as well as the antimicrobial activity of SFT/DT–Au
NDs were also studied, and it was shown that these characteristics are highly dependent on the density
of SFT on Au NDs. Relative to SFT, SFT/DT–AuNDs exhibited greater antimicrobial activity, not
only to non-multidrug-resistant bacteria but also to the multidrug-resistant bacteria. The minimal
inhibitory concentration values of SFT/DT–AuNDs were much lower (>80-fold) than that of SFT.
The authors considered that the antimicrobial activity of SFT/DT–AuNDs was mainly achieved by
the synergistic effect of SFT and DT–AuNDs on the disruption of the bacterial membrane. In vitro
cytotoxicity and hemolysis, analyses were also performed and had revealed superior biocompatibility
of SFT/DT–AuNDs than that of SFT. Moreover, in vivo methicillin-resistant S. aureus infected wound
healing studies in rats showed faster healing, better epithelialization. This study suggested that
the SFT/DT–AuNDs system may be a promising antimicrobial candidate for preclinical applications
in treating wounds and skin infections [39]. Rai et al. also reported a one-step methodology to
generate AMP-conjugated (AuNPs) [40]. The AMP-conjugated AuNPs prepared showed controlled
size (14 nm) and low polydispersity and allowed the inclusion of high concentration of AMPs.
Further, these systems demonstrated higher antimicrobial activity and stability in serum and in the
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presence of non-physiological concentrations of proteolytic enzymes than soluble AMP, as well as low
cytotoxicity against human cells [40]. Interestingly, Akrami et al. showed the possibility to exploit
gold NPs as a novel anticancer platform [41]. Results of this research confirm the improvement of cell
internalization of gold NPs, with higher cytotoxicity and cellular uptake for smaller NPs compared
to larger nanospheres and nanorods, suggesting that anticancer effects of the selected peptides were
modulated by the size and shape of the gold nanoparticles [41].
4.1.2. Silver Nanoparticles
Geilich et al. developed novel delivery systems by combining silver NPs and ampicillin so to
achieve a synergistic dose-dependent effect on bacterial cells [42]. The obtained polymersomes were
safe on human fibroblasts and more effective in inhibiting bacterial cells with a silver-to-ampicillin ratio
of one to 0.64, respectively. Recent advances in AMP delivery by Ag nanostructures, Pazos et al. [43]
reported on supramolecular assemblies of novel peptide amphiphiles (PAs) containing aldehyde
functionality in order to reduce Ag ions and subsequently nucleate Ag metal NPs in water. This
proposed system spontaneously generates monodisperse Ag particles at regular distances along
the length of the filamentous organic assemblies. The metal−organic hybrid structures exhibited
antimicrobial activity and significantly less toxicity toward eukaryotic cells. Metallized organic
nanofibers of the type described offer the possibility to create other structures. For instance, hydrogels,
that can be potentially applied in wound dressing development [43]. Also addressing the wound
infection problem, Salouti et al. investigated the synergistic antibacterial effect of plant peptide MBP-1
and AgNPs on infected wounds caused by S. aureus [44]. The MIC and MBC of MBP-1 and AgNPs
both on their own and in combination form were determined against S. aureus via macrodilution and
microdilution methods. The MIC and MBC of MBP-1 were found to be 0.6 and 0.7 mg/mL, respectively.
MIC and MBC of AgNPs were determined to be 6.25 and 12.5 mg/L, respectively. MIC and MBC
of the AgNPs and MBP-1 combination were found to be 3.125 mg/mL, 0.5 mg/L; and 6.25 mg/mL,
0.6 mg/L, respectively. The synergistic antibacterial effect of Ag NPs and MBP-1 was investigated
on infected wounds caused by S. aureus in a mouse model, and the infected wound healed properly
after the combined use of MBP-1 and AgNPs [44]. It is worth to note recent findings by Chaudhari
et al. concerning the conjugation of silver-coated carbon nanotubes with the antimicrobial peptide
TP359. Herein, authors underline the occurrence of an additive effect of silver-coated nanotubes and
TP359 regarding antibacterial activity. The innovative nano-system was found to be safe to murine
macrophages and Hep2 cells at the MIC concentrations [45].
4.1.3. Silicon Nanostructures
As delivery systems for AMPs, silicon and silicon derivates nanostructures have also been
investigated recently. Membrane interactions are critical for the successful use of mesoporous SiNPs.
In order to elucidate these, Braun et al. have studied the effects of NP charge and porosity on AMP
loading and release, as well as consequences of this for membrane interactions and antimicrobial
effects [46]. Anionic mesoporous SiNPs were found to incorporate considerable amounts of the CAMP
LL-37, whereas loading was found to be much lower for non-porous or positively charged SiNPs.
The results also demonstrated that due to preferential pore localization, anionic mesoporous particles,
but not the other particles, protects LL-37 from degradation by infection-related proteases. For anionic
SiNPs, membrane disruption is mediated almost exclusively by peptide release. In contrast, non-porous
SiNPs built up a resilient LL-37 surface coating due to their higher negative surface charge, and display
largely particle-mediated membrane interactions and antimicrobial effects. For positively charged
mesoporous SiNPs, LL-37 incorporation promoted the membrane binding and disruption displayed
by the particles in the absence of peptide, but also caused toxicity against human erythrocytes. Thus,
the use of mesoporous SiNPs as AMP delivery systems requires consideration of membrane interactions
and selectivity of both free peptide and the peptide-loaded NPs [46]. The properties of AMPs adsorbed
on inorganic or organic surfaces are of interest for their potential applications in intracellular drug
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delivery. In the work of Syryamina et al., continuous-wave (CW) electron paramagnetic resonance
(EPR) and pulsed electron-electron double resonance (PELDOR) techniques were applied to study
the adsorption of the AMPs trichogin GA IV and ampullosporin A on monodisperse colloidal silica
nanospheres (SiNS) of 20 nm diameter [47]. The results obtained by CW EPR supported the view
that the adsorbed peptides form close-packed clusters. PELDOR data show that both trichogin and
ampullosporin adsorbed on the silica surface possess a more disordered conformation as compared to
that in solution. For ampullosporin, disordering is much more pronounced than for trichogin. After
desorption, the peptides restored their conformations; upon adsorption, the peptides in some cases
may lose partly their biradical character [47]. These results may be of interest as the antimicrobial
activity is often related to peptide conformation.
Nano-clays or layered silicates are an interesting nanostructure that has been used for remediation
of environmental contaminants, delivery of drugs and various active molecules, and to enhance
polymer mechanical and barrier properties in packaging films. They typically present a stacked
arrangement of silicate layers with a nanometric thickness [62]. Meira et al. studied three different
nano-clays (bentonite, octadecylamine-modified montmorillonite, and halloysite) as potential carriers
for the AMPs nisin and pediocin, known bacteriocins, the first referred above as having application
as a food preservative. Higher adsorption at room temperature of nisin and pediocin was obtained
on bentonite. The antimicrobial activity of the resultant bacteriocin-nano-clay systems was analysed
using skimmed milk agar as food simulant, and the largest inhibition zones were observed against
Gram-positive bacteria for halloysite samples. Bacteriocins were intercalated into the interlayer space
of montmorillonites as deduced from the increase of the basal spacing measured by X-ray diffraction
(XRD) assay. These results indicate that nano-clays, especially halloysite, are suitable nano-carriers for
nisin and pediocin adsorption, and the results may be considered interesting for the food industry [48].
4.2. Polymeric Nanoparticles for AMP Delivery
Different biodegradable polymeric nano-systems have been explored as carriers for antimicrobial
agents that exhibit a high bactericidal activity. The efficacy of this strategy is well proven, highlighting
polymeric nano-systems can effectively improve the cellular penetration, intracellular retention and
specific subcellular distribution of antimicrobial agents, and even evade intracellular inactivation of
antimicrobial agents [63].
Controlled drug release using biocompatible and biodegradable polymers further emerged in the
1980s [64]. After the first polymer-based delivery of macromolecules using poly[ethylene vinyl acetate]
polymer was demonstrated in 1976 [65,66]. Antimicrobial drug delivery using polymeric NPs offers
several advantages: (i) structural stability in biological fluids and under harsh and various conditions
for preparation; (ii) precisely tuneable properties, such as size, zeta-potentials, and drug release profiles,
by manipulating polymer lengths, surfactants, and organic solvents used for NP preparation [67],
and (iii) facile and versatile surface functionalization for conjugating drugs and targeting ligands [68].
Concerning antimicrobial nanoparticulate delivery systems, two major types of polymers have
been explored: linear polymers (e.g., polyalkyl acrylates and polymethyl methacrylate) and amphiphilic
block copolymers. The majority of polymeric NPs prepared with linear polymers are nano-capsules or
solid nanospheres [69]. In polymeric nano-capsules, a polymeric membrane that controls the release
rate surrounds the drugs that are solubilized in aqueous or oily solvents. In solid nanospheres, drugs are
homogeneously distributed in the polymeric matrices of variable porosities [70,71]. Amphiphilic block
copolymers form self-assemble micellar NPs with the drug being encapsulated in the hydrophobic
core and surrounded by a hydrophilic shield. This shied allows the core to be protected from
degradation [72]. Several biodegradable polymers, including poly(lactic acid) (PLA), poly(glycolic
acid) (PGA), poly(lactide-co-glycolide) (PLGA), poly(caprolactone) (PCL), and poly(cyanoacrylate)
(PCA), have been used as the hydrophobic core of the amphiphilic copolymers, whereas PEG has been
the most commonly used hydrophilic segment [67,73–76]. Targeting ligands can also be conjugated on
the termini of PEG for targeted and selective delivery [77,78].
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Polymeric NPs have been explored to deliver various antimicrobial agents and greatly enhanced
therapeutic efficacy in treating many types of infectious diseases has been reported. For instance,
encapsulated ampicillin in polymeric NPs was effective for S. typhimurium infection treatment [79] and
intracellular L. monocytogenes infection in mouse peritoneal macrophages [80]. The use of polymeric
NPs can overcome the limited oral administration of unstable or inadequately absorbed drugs, [81]
and, in addition, PEGylation of NPs, can increase drug half-life in serum, and improve mucoadhesive
capabilities by reducing phagocytosis [82] Thus, among nanoparticle platforms, polymer NPs may be
the most suitable system that can be used for antimicrobial drug delivery.
Biodegradable polymers and bioorganic polymers are also promising materials in the delivery
of peptide-based drugs due to their compatibility, degradation behaviour, and nontoxic nature of
administration [83]. The development of polymeric therapeutic nanostructures for AMP delivery may
offer an excellent technological strategy to improve drug bioavailability and safety. CS-based NPs
(CSNPs) are particularly interesting as the broad spectrum of antibacterial activity of CS is well known
and documented, offering the possibility of synergistic effects with antimicrobial molecules. Moreover,
due to its biocompatibility properties, CS nanostructures have been extensively studied for drug
delivery, and that is no different for AMP delivery. In fact, the majority of the studies performed so far
involves CS nanostructures and was already revised in previous work [84] from which we reproduce
Table 4. Research has been covering, the technological development of new carrier systems and their
full characterization, and the evaluation of their efficacy as drug delivery improvers. In addition to
CS-based nanostructures, recent studies on other polymeric nanostructures for AMP delivery have
been developed (Table 5).
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Table 4. Recent studies on CS based nanoparticles for AMP delivery.
System AMP Study Description Authors
NPs
CS-alginate nano-capsules - Development of nano-capsules carriers for bioactive compounds, produced through LbLtechnique using, 5-aminosalycilic acid and glycomacropeptide model. Rivera et al. [85]
CS-based nanoparticles Vancomycin CS particles were prepared by ionic gelation and freeze-drying or spray-drying as recoverymethods. Antibacterial activity against S. aureus. Cerchiara et al. [86]
CS-based nanoparticles Lysozyme as model Development of a nanoparticle model with commercially available CS loaded with lysozymeas antimicrobial protein drug model. Piras et al. [87]
CS and poly-gamma-
glutamic acid composites LL-37
The results indicated that both LL-37 and NO were co-loaded successfully in micro particles,
and the composite particles could sustain LL-37 and NO release at physiological pH, in vitro. Sun et al. [88]
CS tripolyphosphate
(CS-TPP) nanoparticle Cryptdin-2
Preparation of CS tripolyphosphate (CS-TPP) NPs by ionotropic gelation. The formulation was
then characterized on the basis of particle size, zeta potential and polydispersity,
and antimicrobial in vivo assays against Salmonella enterica were performed.
Rishi et al. [79]
CS-based nanoparticles Temporin B
CS-NPs were prepared based on the ionotropic gelation between CS and sodium
tripolyphosphate. The nano-carrier evidenced a sustained antibacterial action against various
strains of S. epidermidis.
Piras et al. [89]
Nanogels
Nanogel composites -
Prepation of AgNPs embedded in a biocompatible nanogel comprising degradable, natural
polymers. In this study, hybrid nanogels were prepared with varying polymer content and
their potential by determining their antibacterial properties against E. coliand S. aureus strains.
Coll Ferrer et al. [90]
Glycol- CS nanogels -
Study of the biocompatibility of a glycol CS nanogel by evaluation of effects on metabolic
activity, cell cycles blood compatibility. Overall, the results demonstrated the safety of the use
of the GC nanogel as drug delivery system.
Pereira et al. [91]
Nanofibers and films
CS thin films hLF1-11
Immobilization performed onto CS thin films as a model for an implant coating due to its
reported osteogenic and antibacterial properties. CS thin films were produced by spin-coating
on Au surfaces. Activity against methicillin-resistant S. aureus (MRSA).
Costa et al. [92]
Nanofibers
Defensin-1,
Dermaseptin
LL-37
Magainin 1
Alternate deposition of polycation (CS) and polyanion over cotton gauzes. Antimicrobial
assays were performed with two strains: S. aureus and K. pneumonia. Gomes et al. [92]
Food packaging systems
CS films Nisin
Study of the efficiency as antimicrobial carriers of hydroxypropyl methylcellulose [93],
chitosan (CS), sodium caseinate (SC) and polylactic acid [93] films, in the release rates of
fluorescently labeled nisin Z, evaluating their potential as food packaging polymers.
Imran et al. [93]
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Table 5. Recent studies on other polymeric nanoparticles for AMP delivery.
System AMP Study Description Authors
NPs
PLGA nanoparticles Colistin Development of a system of nano-embedded microparticles (NEM) for sustained delivery ofCAMPs in the lung D’Angelo et al. [94]
PLGA nanoparticles Plectasin Intracellullar antibacterial activity against S. aureus in epithelial cells. Water et al. [23]
Hydro- and Nanogels
Self-assembled 3-D hydrogels MD-CAMPs Study of bactericidal activity compared to MD-CAMPs in solution, and rheological properties. Jiang et al. [95]
Hyaluronic acid nanogel Novicdin Quality-by-design novel nanogel-based novicidin delivery system. Water et al. [96]
PLLA-L35-PLLAin situ gel AP-57 Potential application of AMPs in wound healing, by developing a biodegradable poly(L-lactic acid)-Pluronic L35-poly (L-lactic acid) (PLLA-L35-PLLA) in situ gel-forming system Li et al. [97]
Food preservation systems
Pectin nanoparticles Nisin Study of a safe suitable antimicrobial system to be used in food industry. Influence of pectindegree of acetylation on NP properties. Krivorotova et al. [98]
Chitosan/PGA nanoparticles Nisin Influence of chitosan coating on colloidal stability, loading capacity and encapsulation efficiency Wu et al. [99]
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D’Angelo et al. designed and developed a system of nano-embedded microparticles (NEM) for
sustained delivery of cationic AMPs (CAMPs) [94] in the lung, studying its effect on P. aeruginosa,
a known lung infection pathogen. To this purpose, PLGA NPs containing a model CAMP, colistin (Col),
were produced by the emulsion/solvent diffusion technique, and then spray-dried in different carriers
(lactose or mannitol), thus producing NEM. The most promising NEM formulations were selected
from bulk and flow properties, distribution of NPs in the carrier and aerosolization performance
upon delivery through a breath-actuated dry powder inhaler. Col–loaded NEM were found to kill P.
aeruginosa biofilms and to display a prolonged efficacy compared to the free Col. [94]. Another CAMP,
plectasin, was encapsulated into PLGA NPs using the double emulsion solvent evaporation method,
in the work of Water et al. [23] The plectasin-loaded NPs displayed a high encapsulation efficiency
(71–90%) and mediated release of the peptide over 24 h. The antimicrobial efficacy was investigated
using bronchial epithelial Calu-3 cell monolayers infected with S. aureus, and encapsulated plectasin
displayed improved efficacy as compared to non-encapsulated plectasin. The author also assessed the
subcellular localization of the prepared NPs in different relevant cell lines: Calu-3 epithelial cells, THP-1
macrophages and A549 epithelial cells. Here the results have shown good patterns of penetration on
Calu-3 epithelial cell lines, as well as in THP-1 macrophages [23].
Hydrogels and nanogels are an important class of biomaterials that have been widely utilized
for a variety of biomedical/medical applications. The biological performance of these systems,
particularly those used as wound dressing; can be complemented with antimicrobial activity capable
of preventing colonization of the wound site by opportunistic bacterial pathogens [90,100,101]. These
types of structures have also been studied recently for AMP delivery. Continuing their study of the
antimicrobial activity of multi-domain CAMPs (MD-CAMPs) in solution, Jiang et al. investigated
the same effect of self-assembled 3-D hydrogels supramolecular nanostructures and its rheological
properties [95]. Among the studied MD-CAMPs solutions, the bactericidal activity of peptide hydrogels
was found to be improved. The improved antimicrobial activity of the self-assembled peptide hydrogels
was found to be related to the combined effect of supramolecular surface chemistry and storage modulus
of the bulk materials, rather than the ability of individual peptides/peptide assemblies to penetrate
bacterial cell membrane as observed in solution. Thus, the structure–property–activity relationship
developed through this study may provide important knowledge for designing biocompatible peptide
hydrogels with built-in antimicrobial activity for various biomedical applications [95]. The Water et al.
group also designed novel nanogel-based novicidin delivery system. The peptide novicidin was
self-assembled with a nano-ctenyl succinic anhydride-modified analogue of hyaluronic acid, and this
formulation was optimized using a microfluidics-based quality-by-design approach. The encapsulation
efficiency of novicidin (15–71%) and the zeta potential (−24 to −57 mV) of the nanogels could be
tailored by changing the preparation process parameters, with a maximum peptide loading of 36 ± 4%.
The nanogels exhibited good colloidal stability under different ionic strength conditions and allowed
complete release of the peptide over 14 days. Furthermore, self-assembly of novicidin with hyaluronic
acid into nanogels significantly improved the safety profile at least five-fold and six-fold when tested
in HUVECs and NIH 3T3 cells, respectively, while showing no loss of antimicrobial activity against
E. coli and S. aureus [96]. Li et al. explored the potential application of AMPs in wound healing, by
developing a biodegradable poly(L-lactic acid)-Pluronic L35-poly(L-lactic acid) (PLLA-L35-PLLA) in
situ gel-forming system [97]. An injectable formulation composed of human AMPs 57 (AP-57) loaded
NPs, and thermosensitive hydrogel was prepared. AP-57 peptides were enclosed with biocompatible
NPs (AP-57-NPs) with high drug loading and encapsulation efficiency. AP-57-NPs were further
encapsulated in a thermosensitive hydrogel (AP-57-NPs-H) to facilitate its application in cutaneous
wound repair. As a result, AP-57-NPs-H released AP-57 in an extended period and exhibited quite
low cytotoxicity and high anti-oxidant activity in vitro. The in vivo wound healing assay using a
full-thickness dermal defect model of SD rats indicated that AP-57-NPs-H could significantly promote
wound healing. At day 14 after an operation, the treated group showed nearly complete wound closure
of 96, 78 ± 3, 12% [97]. Other studies of nisin nanoencapsulation were performed, with the purpose of
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protection to ensure the stability of this AMP during food processing and storage period. Nisin-loaded
pectin NPs (NLP-NPs) were prepared and analysed by Krivirotova et al. by a simple complexation
method [98]. Three types of pectin biopolymer were tested and it was found that the methoxylation
degree of pectin influenced nisin loading efficiency and particle size. For the complex formation,
both electrostatic and hydrophobic interactions were important. NLP-NPs exhibited antimicrobial
activity that was dependent on the type of biopolymer. Overall, the results indicated that NLP-NPs
might be a suitable antimicrobial system to be used in the food industry [98]. Nisin nanoencapsulation
in self-assembly chitosan- and poly- glutamic acid, was recently reported by Wu et al. [99]. Herein,
the authors showed that the use of a coating layer of chitosan improved colloidal stability, loading
capacity and encapsulation efficiency. Furthermore, chitosan layer composite nanoparticles were
more effective compared to uncoated NPs and nisin in inhibiting the growth of Escherichia coli and
Listeria monocytogenes.
4.3. Lipid Nanoparticles for AMP Delivery
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) stand for nanoparticles
composed of lipid materials that melt at temperatures above 40 ◦C [102]. Their main purpose is to
modify the release profile of the payload attributed to their solid core. While SLN are composed of
solid lipids only, NLC matrix is a blend of solid and liquid lipids (which also melts above the body
temperature) to improve the solubility of lipophilic compounds. Both SLN and NLC are biodegradable
and non-toxic [103–105], and their versatility of is also attributed to their capacity to load a range of
chemically different bioactives, including peptides and proteins [106–109], and be modified on their
surface [110,111]. Fumakia et al. have developed SLN for the simultaneous delivery of an endogenous
host defence peptide (LL37) with antimicrobial activity and an elastase inhibitor serpin A1 (A1) for
the treatment of wound infections [112]. The authors reported that SLN could modify the release
profile of simultaneous delivery of both bioactives, accelerate wound healing in BJ fibroblast cells and
keratinocytes and promote antibacterial activity against Staphylococcus aureus and Escherichia coli in
comparison to LL37 or A1 alone.
LL37 loaded into NLC have also been proposed by Garcia-Orue for the topical treatment of chronic
wounds [113]. LL37-loaded NLC did not affect cell viability tested against human foreskin fibroblasts
while the in vitro bioactivity assay showed that the peptide remained active after the loading into
lipid nanoparticles as the system reversed the macrophages activation as happened with the LL37 in
solution. LL37-loaded NLC were also active against Escherichia coli. The in vivo testing in mice also
demonstrated the systems’ capacity to improve healing by promoting wound closure, reepithelization
grade and restoration of the inflammatory process.
Lewies et al. demonstrated that biodegradable NLCs enhance the antibacterial activity of
antimicrobial peptides [114]. The authors have studied the effect of nisin Z when loaded into
nanostructured lipid carriers on Staphylococcus aureus, Staphylococcus epidermidis and Escherichia coli.
Nisin Z exhibited additive interactions with numerous conventional antibiotics, in particular, with
novobiocin. The presence of EDTA improved the antimicrobial activity of free nisin Z towards
Escherichia coli significantly. Nisin Z-loaded NLCs were effective against Gram-positive species at
physiological pH, also showing an increased efficacy when adding EDTA. Nisin Z-loaded NLCs
were shown potential to enhance the antibacterial activity of nisin Z towards Gram-positive bacteria
commonly found in skin infections.
4.4. Other Nanostructures for AMP Delivery
Other types of nanomaterials, such as dendrimers and carbon nanodots, have also been successfully
proposed for the delivery of AMPs. Due to their ease of synthesis and low manufacturing costs,
antimicrobial polymers including dendrimers have been exploited to mimic the antibacterial mechanism
host defence peptides, by compromising bacterial cell membranes [115]. Gide et al. developed
nanomaterials-lipidated amphiphilic dendrimers which displayed potent and selective antimicrobial
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activity against both Gram-positive and Gram-negative bacteria, including multidrug-resistant
strains [115]. These dendrimers are also shown to inhibit bacterial biofilms effectively.
Carbon nanodots or carbon quantum dots were originally discovered due to their bright
fluorescence emissions as those found in conventional semiconductor quantum dots, and can also be
used for drug delivery [116]. Carbon dots modified with vancomycin were proposed for the treatment
of Gram-positive bacterial infections [117]. Zhong et al. synthesized surface-modified carbon dots with
vancomycin and successfully tested them against Bacillus subtilis, Listeria monocytogenes, Salmonella,
Pseudomonas aeruginosa and Escherichia coli. The modified carbon dots showed affinity to the tested
Gram-positive bacteria owing to the ligand–receptor interactions between vancomycin and the cell walls.
Pramanik et al. synthesis red/blue fluorescent carbon dot-attached magnetic nanoparticles for selective
separation and identification of superbugs from infected blood samples [118]. The nanoparticles were
capable of isolating methicillin-resistant Staphylococcus aureus (MRSA) and Salmonella DT104 superbug
from whole blood samples, followed by accurate identification via multicolor fluorescence imaging.
The authors also described the design of antimicrobial peptide-conjugated multicolor fluorescent
magneto-carbon dots for separation, identification and disinfection of multidrug resistance superbugs
from infected blood.
5. Conclusions and Future Challenges
AMPs are antimicrobial compounds recognized as among the most promising drug candidates
against infections. They exhibit distinct mechanisms of action and may show additional biological
activities, e.g., as signalling molecules and biomarkers, and even as tumoricidal agents. AMPs, however,
show low stability and bioavailability. The formulation of AMPs into nanomaterials seems to offer
a very appealing and effective manner to improve these limitations, and several systems have been
designed and studied for this purpose (e.g., inorganic, polymeric and lipid nanoparticles, carbon
dots and dendrimers). However, concerns on how to regulate the distribution of nanomaterials in
the body or specific organs are also raised. Nano-drugs are foreign substances to the body and may
produce inflammation. Therefore, safety data for long-term therapy or repeated dosage are needed to
circumvent the potential risk. Biodegradable nanomaterials have been proposed to reduce the risk of
toxicological events both in vitro and in vivo. To date, few studies have investigated the toxicological
and environmental effects of direct and indirect exposure to nanomaterials, and no clear guidelines
exist to quantify these effects. Therefore, there is an urgent need for developing guidelines, which can
assure the safe use of nanomaterials. Moreover, more powerful ex vivo models or animal models are
needed to assess the safety issues and to comply with government regulations. How to extend the shelf
life of nanodrugs is also a problem due to their agglomeration also being a problem. The production
methods for nanostructures should also be improved, and scalable studies for industrial production
are also of great importance in order to promote cost effectiveness of these new formulations. The cost
and production of nanomaterials on a large scale is one of the hurdles in effective implementation of
these products. Hence, the scientific community should also pay attention to developing affordable
methodologies so that nanotechnology can reach patients. In conclusion, it seems that, although the
promising research results in this area are rising, it is also urgent to start directing efforts in making
these new drug formulations a reality as therapeutic agents.
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